{"schema_version":"secwatch.filing_event.v1","accession":"0001544784-24-000068","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.408632+00:00","generated_at":"2026-06-01T22:37:48.427674+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path Q1 net loss $3.2M ($4.88/sh); raises $3.5M post-quarter","bullets":["Net loss $3.2M ($4.88 EPS) vs $5.3M ($13.25 EPS) in Q1 2023; R&D expense down to $2.3M from $4.0M.","Cash at Mar 31 only $0.2M; raised $3.5M in April via $1.2M direct offering and $2.3M ATM sales.","Completed second dose cohort (40 mg/m2) of Phase 1/1b BP1002 trial for relapsed AML; pause for FDA review.","Patent portfolio expanded to 5 U.S. and 54 foreign patents covering 21 countries; new applications filed.","First dose cohort of Phase 1 BP1002 trial for relapsed lymphoma/CLL completed in January."],"urls":{"canonical":"https://secwatch.observer/filing/0001544784-24-000068","json":"https://secwatch.observer/filing/0001544784-24-000068.json","markdown":"https://secwatch.observer/filing/0001544784-24-000068.md","text":"https://secwatch.observer/filing/0001544784-24-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/0001544784-24-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/bpth-20240515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:37:48.427674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a86fdaad0fd0acad969566cf4861abae68c7c352","claim":"BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income $3.2 million, or $4.88 per share, EPS $4.88 per share.","evidence_excerpt":"The Company reported a net loss of $3.2 million, or $4.88 per share, for the three months ended March 31, 2024, compared to a net loss of $5.3 million, or $13.25 per share, for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/0001544784-24-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$3.2 million, or $4.88 per share"},{"label":"EPS","value":"$4.88 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}